CompletedNot Applicable

Glucagon in MODY (Maturity Onset Diabetes of the Young)

United Kingdom10 participantsStarted 2017-07-03

Plain-language summary

The aim of this study is to determine whether fasting and post-prandial glucagon secretion is suppressed by gliclazide in patients with HNF1-/4-alpha MODY. Participants will undergo an oral glucose tolerance test (OGTT) before and after omitting their gliclazide medication for 3 days.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of HNF1-alpha or HNF4-alpha MODY. * Currently on gliclazide treatment Exclusion Criteria: * Currently taking any anti-diabetic medication other than gliclazide and metformin * Oral steroid treatment 30 days prior to the start or at any time during the study period. * Known malignancy or any other condition or circumstance which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol. * Felt to be unsuitable to participate in the study in the opinion of the Chief Investigator. * Currently participating in a clinical trial involving an anti-diabetic medication

What they're measuring

Change in plasma glucagon from baseline (0min)

Timeframe: 0min, 30min, 60min, 90min and 120min during 75g oral glucose tolerance test.

Trial details

NCT IDNCT03246828

SponsorUniversity of Oxford

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-07-29

View on ClinicalTrials.gov More MODY1 trials